As reported on Science Daily, a novel CRISPR-driven RNA editing strategy could help overcome one of the biggest challenges in prostate cancer treatment: resistance to immunotherapy. Researchers have demonstrated that…
As reported on Stock Titan, the European Commission has approved Enhertu® (trastuzumab deruxtecan) as a treatment for adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) solid tumors who…
As reported on Inside Precision Medicine, scientists have developed a way to spot a specific lung cancer mutation in just minutes instead of weeks, using a combination of advanced laser…
As reported on Business Wire, Delcath Systems has announced the enrollment and dosing of the first patient in its global Phase 2 DELUMA clinical trial, marking a significant step in…
As reported on Science Daily, scientists have combined polymer-coated nanoparticles with therapeutic drugs for cancer treatment, including treatment for ovarian cancer. The nanoparticles target tumors and subsequently release their payloads,…
The pharmaceutical company Grifols—has started dosing patients in the final stage (Phase 3) of two clinical trials. The company is trying to get approval to use two of its antibody-based…
Merck has reported positive topline findings from the Phase 3 KEYNOTE-C93 trial, demonstrating that pembrolizumab (KEYTRUDA®) significantly extended progression-free survival (PFS) compared with standard platinum-based chemotherapy in patients with mismatch…
As reported on Vermont Biz, researchers at the University of Vermont (UVM) and biotechnology company RS Oncology have reported encouraging results from an early-stage clinical trial of a novel treatment…
As reported by The Manila Times, the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Elevar Therapeutics regarding its new drug application for the…
Editor's Note: Patient Worthy is honored to share this interview, featuring Kate, an ovarian cancer survivor, and Dr. Premal Thaker, M.D. “There is fear, and there are hard days, but…
New research from the 2026 American Society of Clinical Oncology (ASCO) annual meeting, and presented on Cure Today, highlights an encouraging new treatment on the horizon for advanced non-small cell…
Editor's Note: Patient Worthy is honored to share this article from our friend Abigail Johnston, originally published on her blog No Half Measures. To see the article in its original…
Early Clinical Results Highlight Potential New Treatment Strategy As reported on STAT News, a novel investigational drug combination developed through a collaboration between Tango Therapeutics and Revolution Medicines has demonstrated…
As reported by PharmaBiz, Eli Lilly and Company has announced positive findings from its Phase 3 BRUIN CLL-322 trial evaluating pirtobrutinib (Jaypirca), a next-generation non-covalent Bruton tyrosine kinase (BTK) inhibitor,…
As reported on MedCity News, Eli Lilly has reported encouraging early-stage clinical data for AJ1-11095, an investigational therapy for myelofibrosis acquired through its recent purchase of Ajax Therapeutics. Findings, presented…
As reported on Yahoo News, a combination therapy involving nivolumab (Opdivo) from Bristol Myers Squibb and cabozantinib (Cabometyx) from Exelixis has demonstrated substantial clinical benefit in patients with previously untreated…
As reported on Pharmaceutical Technology, the US Food and Drug Administration (FDA) has approved a new adjuvant treatment option for adults with clear cell renal cell carcinoma (ccRCC) at elevated…
I grew up believing health was something you could control if you were disciplined enough. In my Chinese immigrant family, my father talked constantly about how fried food and Western…
In a notable update for dermatologic and consumer health, the U.S. Food and Drug Administration (FDA) released a press statement disclosing their authorization of the use of bemotrizinol as an…
As reported on Becker's Hospital Review, the U.S. Food and Drug Administration’s launch of a real-time clinical trial model marks a notable shift in how oncology research is conducted and…
As reported on Business Wire, Onchilles Pharma has announced the first patient dosing in a Phase 1/2 clinical trial evaluating its investigational therapy, N17350, in individuals with advanced solid tumors.…
As reported on STAT News, a novel combination of investigational therapies from Tango Therapeutics and Revolution Medicines is generating cautious optimism after demonstrating notable tumor responses in an early-stage clinical…
Merck and Gilead Sciences reported contrasting late-stage outcomes on Monday, pairing a promising advance in HIV treatment with the discontinuation of a high-profile lung cancer trial after underwhelming survival results.…
As reported on Business Wire, Stanford Medicine Cancer Center has reported a significant milestone in radiation oncology, completing the world’s first patient treatment using a compact upright proton therapy system.…
As reported by The Manila Times, MediciNova has announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a new patent application involving its investigational…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
